DRC Ebola Outbreak Tops 6,000 Cases as Bundibugyo Virus Deaths Pass 3,000

Why this outbreak is different

The current Ebola outbreak in the Democratic Republic of the Congo (DRC) is caused by the Bundibugyo virus, a species of Orthoebolavirus that behaves differently from the Zaire strain behind most past epidemics. It is now the second-largest Ebola outbreak on record — and by some measures the fastest-growing — with transmission occurring increasingly outside known contact chains. For health professionals, it is a reminder that Ebola is no longer a contained, central-African curiosity: it is a live, expanding emergency with real implications for surveillance, triage and travel medicine worldwide.

The outbreak in numbers

As of 31 August 2026, the DRC had reported 6,186 confirmed cases and 3,007 deaths, according to data released on 1 September. More than 1,400 patients have recovered, and around 830 remain hospitalised in isolation.

• Case fatality ratio: roughly 48–49% among confirmed cases
• Geographic spread: 60 health zones across six of the DRC’s 26 provinces
• Epicentre: Ituri province — 5,065 cases and 2,305 deaths across 28 health zones
• Other affected provinces: North Kivu (868 cases), Haut-Uélé (227), Tshopo (19), South Kivu (3) and Bas-Uélé (4)
• Daily momentum: more than 80 new confirmed cases were still being reported per day in late August

Regional and international spread

The outbreak has not stayed inside the DRC. Uganda reported 20 cases between May and June 2026, including two deaths, before declaring the outbreak over on 25 August after completing a 42-day monitoring period. Two US citizens infected while working in the DRC were medically evacuated to Germany for treatment, and a French humanitarian doctor who returned from the affected region was treated in France and recovered.

WHO surveillance identified 76 Ebola-related signals across 23 countries and territories between 18 May and 28 August. Most were ruled out through investigation and laboratory testing, but six were confirmed as Ebola events — underscoring how quickly this virus can move across borders when conflict and displacement disrupt screening.

No proven vaccine — yet

One of the most challenging features of this outbreak is that no vaccine or specific treatment is licensed for the Bundibugyo virus. The licensed Ervebo® vaccine protects against Zaire ebolavirus, but it is not yet known whether it protects humans against Bundibugyo.

On 27 August, vaccination of healthcare workers with Ervebo began in parts of the DRC, including Kisangani in Tshopo province, alongside a clinical trial designed to answer exactly that question. The trial is considered critical: if Ervebo proves effective, response teams gain a powerful new tool; if not, the world still lacks a countermeasure for a virus that has now killed thousands.

How Bundibugyo virus spreads

Bundibugyo virus disease (BVD) is a zoonotic infection. Fruit bats are the suspected natural reservoir, and human infection is thought to begin through contact with the blood or secretions of infected wildlife such as bats or non-human primates. From there, the virus spreads person-to-person:

• Direct contact with the blood, secretions, organs or other bodily fluids of an infected person
• Contact with contaminated surfaces and materials, including bedding and medical equipment
• Healthcare settings where infection prevention and control (IPC) measures are inadequate
• Unsafe burial practices involving direct contact with the deceased

The incubation period ranges from 2 to 21 days, and people are not infectious until symptoms appear — which is why early recognition and isolation matter so much.

Signs and symptoms to know

Early BVD symptoms are frustratingly non-specific: fever, fatigue, muscle pain, headache and sore throat. The illness then typically progresses to gastrointestinal symptoms — vomiting, diarrhoea, abdominal pain — and can advance to organ dysfunction and, in severe cases, bleeding.

For clinicians, the key red flag is a travel or exposure history: fever in someone who has been in affected areas of eastern DRC, or who has had contact with a confirmed case, warrants immediate isolation and notification of public health authorities.

Why the response is struggling

This is not a typical outbreak response. It is unfolding in a conflict-affected region marked by armed violence and large-scale displacement:

• More than 26 million people in the region face acute food insecurity
• Around one million internally displaced people live in Ituri province alone
• Overcrowding, poor water and sanitation, and restricted healthcare access in mining communities and displacement sites make case detection and IPC extremely difficult
• Insecurity restricts access for response teams, hampering surveillance, contact tracing and safe burial teams

Despite this, response teams were following up more than 26,000 contacts in late August, with over 80% seen within 24 hours — an extraordinary effort in extraordinarily difficult conditions. WHO has kept the outbreak classified as a Public Health Emergency of International Concern (PHEIC) following the second meeting of its Emergency Committee on 18 August, and UN officials have called for urgent funding, warning that the response must “outpace” the spread of the virus.

What this means for health professionals

Even for clinicians far from central Africa, this outbreak carries practical lessons. Asking about recent travel to eastern DRC should be part of any fever work-up. Knowing the local protocol for suspected viral haemorrhagic fever — isolation, PPE, and immediate public health notification — can save lives and prevent hospital-based transmission. And for anyone involved in global health, the absence of a licensed Bundibugyo vaccine is a stark reminder of how fragile our defences against emerging viruses remain.

Frequently asked questions

What is Bundibugyo virus disease?

Bundibugyo virus disease is a severe viral illness caused by the Bundibugyo species of Ebola virus (Orthoebolavirus). It causes Ebola-like illness with fever, gastrointestinal symptoms and, in severe cases, organ failure and bleeding. The current outbreak in the DRC began in May 2026.

Is there a vaccine for the Bundibugyo virus?

Not yet. The licensed Ebola vaccine Ervebo® is proven against the Zaire species but its effectiveness against Bundibugyo virus in humans is unknown. A clinical trial launched in late August 2026, alongside vaccination of healthcare workers in affected areas, aims to answer this question.

How is Ebola transmitted between people?

Through direct contact with the blood, bodily fluids, or organs of an infected person — or with contaminated surfaces, clothing or medical equipment. It is not spread through the air. Unsafe burials and inadequate infection control in healthcare settings can amplify transmission.

What are the early symptoms of Ebola?

Fever, fatigue, muscle pain, headache and sore throat — symptoms easily mistaken for malaria, typhoid or flu. Gastrointestinal symptoms typically follow. Anyone with these symptoms and a history of travel to affected areas of the DRC should seek care immediately and disclose their travel history.

Should travellers be worried about the outbreak?

For the general public, including most travellers, the risk of infection remains low. WHO advises against general restrictions on travel or trade with the DRC. Travellers to affected areas should avoid contact with sick people and their body fluids, avoid handling wild animals or raw bushmeat, practise strict hand hygiene, and seek medical attention promptly if fever develops — mentioning their travel history.

Is the outbreak under control?

No. The outbreak is still expanding, with new cases reported daily across six provinces. Uganda has declared its related outbreak over, and imported cases in Germany and France were successfully managed, but sustained transmission in the DRC means the risk of further cross-border spread remains. WHO continues to classify the event as a Public Health Emergency of International Concern.